Type 2 Diabetes

When someone in the hospital needs to see a specialist, particularly a specialty where there are so few of us, I don’t understand how one can just refuse.

Do low-risk CVD patients with T2DM experience the same significantly lower all-cause and CV mortality seen in high-risk patients?

A project from the University of New Mexico looks to turn physicians to experts.

Three studies from ENDO 2017 focused on improving patient care through brain stimulation, an artificial pancreas system, and videoconferencing.

Research presented at ENDO 2017 explored options to reduce complications in patients with diabetes and microalbuminuria and patients with cystic fibrosis.

Physicians have more choices than guidance in picking diabetes drugs.

The DIaMonD and GOLD Studies, which used continued glucose monitoring (CGM) in patients with type 1 diabetes who were in less than optimal control showed that the addition of CGM to these patients’ self-monitoring of blood glucose contributed to lower A1C, more time spent in range, less hypoglycemia, less severe hyperglycemia, and better quality of life.

Studies presented at ENDO 2017 examined the impact of sleep disorders on gestational diabetes, bone formation, and adolescents with and without diabetes.

For Americans, a BMI of 25 means they are overweight. However, a BMI of 23.5 means overweight for Asians. David O’Dell, MD, of the University of Nebraska Medical Center explains why this matters at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

T-scores and FRAX underestimate risk in diabetic patients, she argues.

"Older patients lumped in a group are not all the same,” she says.

The type 1 diabetes patients who were continuously administered testosterone treatment showed improvements in glycemic control as well as massive improvements in their weight loss, since testosterone increases lean body mass.

Farid Saad, DVM, PhD, Bayer Pharma AG learned that the men with type 1 diabetes did experience benefits of long-term testosterone therapy – they showed improvements in their underlying diseases.

Researchers compared time to onset of diabetes in a group of patients with obesity and pre-diabetes treated with liraglutide or placebo.

Diana McNeill, MD, of Duke University Medical Center moderated a panel at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California. The topic of discussion? Personalized care in type 2 diabetes.

Studies include drug-free remission of T2DM, and the impact of hyperglycemia and hypoglycemia on cardiovascular health.

For eyes 20/50 or worse, aflibercept most effective at improving visual acuity.

A small pilot study is the first to report on bone health in people with an at least 50-year history of type 1 diabetes.

Our March list includes Testosterone Trials results, self-management in patients transitioning to adult care, and cancer mortality risk with diabetes.

Research has shown the beneficial effects of empagliflozin on all-cause and CV mortality. Does the same hold true for another SGLT2 inhibitor?

Steven Zelenkofske, DO, vice president of US Medical Affairs at AstraZeneca, talked with MD Magazine about the CVD-REAL study where researchers examined patients with type 2 diabetes taking the new class of diabetes drug, SGLT-2 inhibitors. Positive outcomes were reported with dapagliflozin, canagliflozin, and empagliflozin.

How would you treat glucose excursions in a patient treated with prednisone?

Our February list includes a newly approved drug combo, the ADA’s position statement on diabetic retinopathy, and lifestyle intervention studies.

A new set of guidelines will help people with type 1 diabetes mellitus exercise safely to avoid fluctuations in blood sugar.

The Qatar Study investigated the efficacy of exenatide plus pioglitazone versus basal-bolus insulin in poorly-controlled type 2 diabetes.

Strength training can improve glycemic control among diabetics, but can it reduce rates of type 2 diabetes and cardiovascular disease?

March news includes a possible biomarker for diabetes, a new sensor to read glucose levels, and a study on insulin resistance and bone fracture.

A once-daily dapagliflozin/saxagliptin tablet got FDA approval.

Eight top apps for endocrinologists include decision support tools, printable patient handouts, calculators, and treatment guidelines.